Ritz Justin - Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 58 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Implementation of a Seamless Phase 2/3 Study Design in the Setting of an Emergent Infectious Disease Pandemic: Lessons Learned from the ACTIV-2 Platform COVID-19 Treatment Trial

Mark J Giganti,Kara W Chew,Carlee Moser,Joseph J Eron,Mauricio Pinilla,Jonathan Z Li,Justin Ritz,Arzhang Cyrus Javan, David Alain Wohl,Eric S Daar,Judith S Currier,Davey M Smith, Michael D Hughes, ACTIV-2A540 Study Team

Contemporary clinical trials (2025): 107887-107887

Cited0Views0WOSBibtex

Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial

Kara W. Chew,Brooke McGinley,Carlee Moser,Jonathan Z. Li,Teresa H. Evering,Justin Ritz,Arzhang Cyrus Javan,David Margolis,David A. Wohl,Michael D. Hughes,Eric S. Daar,Judith S. Currier,Joseph J. Eron,Davey M. Smith

The Journal of infectious diseasesno. 1 (2025): 131-136

Cited0Views0WOSBibtex

Severe Acute Respiratory Syndrome Coronavirus 2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients with Coronavirus Disease 2019

Nikolaus Jilg,Mark J. Giganti,Kara W. Chew,Katy Shaw-Saliba,Justin Ritz,Carlee Moser,Teresa H. Evering,Eric S. Daar,Joseph J. Eron,Judith S. Currier,Michael D. Hughes, H. Cliff Lane,Robin Dewar,Davey M. Smith,Jonathan Z. Li

CLINICAL INFECTIOUS DISEASESno. 4 (2024): 920-927

Cited0Views0WOSBibtex

Discontinuation of Tenofovir Disoproxil Fumarate from Initial ART Regimens Because of Renal Adverse Events: an Analysis of Data from Four Multi-Country Clinical Trials

McNeil Ngongondo,Justin Ritz,Michael D Hughes,Mitch Matoga,Mina C Hosseinipour, A52

PLOS Global Public Healthno. 1 (2024): e0002648-e0002648

Cited0Views0WOSBibtex

Post-acute COVID-19 Outcomes Including Participant-Reported Long COVID: Amubarvimab/romlusevimab Versus Placebo in the ACTIV-2 Trial

Teresa H. Evering,Carlee Moser,Nikolaus Jilg,Justin Ritz,David A. Wohl,Jonathan Z. Li,David Margolis,Arzhang Cyrus Javan,Joseph J. Eron,Judith S. Currier,Eric S. Daar,Davey M. Smith,Michael D. Hughes,Kara W. Chew

EClinicalMedicine (2024): 102787-102787

Cited0Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn